The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Subscribe To Our Newsletter & Stay Updated
